Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. 1990

J H Ip, and V Fuster, and L Badimon, and J Badimon, and M B Taubman, and J H Chesebro
Department of Medicine, Mount Sinai Medical Center, New York, New York 10029-6574.

Vascular injury represents a critical initiating event in the pathogenesis of various vascular diseases, including atherosclerosis. This review discusses 1) the current understanding and a new pathologic classification of vascular injury; 2) the resultant cellular pathophysiologic responses, specifically, lipid accumulation, platelet aggregation, thrombus formation and smooth muscle cell proliferation; 3) the role of vascular injury in the pathogenesis of spontaneous and accelerated atherosclerosis; and 4) emerging therapeutic approaches in preventing these vascular diseases. The process of type I vascular injury (nondenuding functional injury) followed by lipid accumulation, monocyte and platelet adhesion, smooth muscle cell proliferation and resultant plaque formation represents the prevalent view of the early stages of spontaneous atherogenesis. The syndromes of accelerated atherosclerosis (namely, heart transplant atherosclerosis, coronary vein graft disease and restenosis after percutaneous transluminal coronary angioplasty) appear to share etiologic mechanisms with spontaneous atherosclerosis by means of the "response to injury" hypothesis. However, type II and type III vascular injury (denuding endothelial and intimal injury with or without medial damage) followed by thrombus and its organization by smooth muscle cell proliferation and subsequent fibrosis appear to be responsible for the vascular process. This accelerated and premature occlusive process accounts for significant morbidity and mortality in patients with these conditions. Better understanding of the nature of vascular injury and its pathophysiologic responses in these clinical situations may aid in developing therapeutic strategies for preventing these vascular diseases.

UI MeSH Term Description Entries
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D001808 Blood Vessels Any of the tubular vessels conveying the blood (arteries, arterioles, capillaries, venules, and veins). Blood Vessel,Vessel, Blood,Vessels, Blood
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D005544 Forecasting The prediction or projection of the nature of future problems or existing conditions based upon the extrapolation or interpretation of existing scientific data or by the application of scientific methodology. Futurology,Projections and Predictions,Future,Predictions and Projections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001161 Arteriosclerosis Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries. Arterioscleroses
D013577 Syndrome A characteristic symptom complex. Symptom Cluster,Cluster, Symptom,Clusters, Symptom,Symptom Clusters,Syndromes
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

J H Ip, and V Fuster, and L Badimon, and J Badimon, and M B Taubman, and J H Chesebro
January 2017, Atherosclerosis,
J H Ip, and V Fuster, and L Badimon, and J Badimon, and M B Taubman, and J H Chesebro
January 2022, Journal of healthcare engineering,
J H Ip, and V Fuster, and L Badimon, and J Badimon, and M B Taubman, and J H Chesebro
January 2023, Frontiers in cardiovascular medicine,
J H Ip, and V Fuster, and L Badimon, and J Badimon, and M B Taubman, and J H Chesebro
January 2023, Journal of healthcare engineering,
J H Ip, and V Fuster, and L Badimon, and J Badimon, and M B Taubman, and J H Chesebro
January 1976, Triangle; the Sandoz journal of medical science,
J H Ip, and V Fuster, and L Badimon, and J Badimon, and M B Taubman, and J H Chesebro
January 1988, Agents and actions. Supplements,
J H Ip, and V Fuster, and L Badimon, and J Badimon, and M B Taubman, and J H Chesebro
January 1996, Seminars in thrombosis and hemostasis,
J H Ip, and V Fuster, and L Badimon, and J Badimon, and M B Taubman, and J H Chesebro
May 2015, Acta physiologica (Oxford, England),
J H Ip, and V Fuster, and L Badimon, and J Badimon, and M B Taubman, and J H Chesebro
February 2020, Canadian journal of physiology and pharmacology,
J H Ip, and V Fuster, and L Badimon, and J Badimon, and M B Taubman, and J H Chesebro
January 2011, Frontiers in bioscience (Landmark edition),
Copied contents to your clipboard!